Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Chemopreventive Agent Development
Sponsor
National Cancer Institute (NCI)
Status
Completed
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT02052908
This randomized phase Ib trial studies the side effects and best dose of naproxen in preventing deoxyribonucleic acid (DNA) mismatch repair deficient colorectal cancer in patients with Lynch syndrome. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of naproxen may keep cancer from forming in patients with Lynch syndrome.
Intervention
Laboratory Biomarker Analysis, Naproxen, Placebo Administration
Condition
Lynch Syndrome
Investigators
Eduardo Vilar-Sanchez